Phaseline

Targets › SOX2

SOX2 (Transcription factor SOX-2): drug programs, companies and trials

2 programs from 2 companies in 6 trials: 4 Phase 2, 2 Phase 1; Oncology, Ophthalmology; next expected readout Apr 2027.

Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Binds to the proximal enhancer region of NANOG (By similarity). (UniProt, P48431)

Open in Phaseline: the race on SOX2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX
ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1Phase 2Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast CarcinomaApr 2027
Life BiosciencesER-100
AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i
OCT4, SOX2, KLF4Phase 1Open Angle Glaucoma (OAG)May 2027

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 (2) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1) Open Angle Glaucoma (OAG) (1)

Modalities

mixed (1), other (1)

Companies

University of Washington (1) Life Biosciences (1)

Related targets

ENG (1) YBX1 (1) CDH3 (1) MDM2 (1) CD105 (1) YB1 (1) OCT4 (1) KLF4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.